A Single Center, Non-randomized, Single Blind, Placebo Controlled, Single Dose Study of the Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients - Phase 1 Study

NCT01120912 Phase 1 COMPLETED

The study will be a non-randomized, open label, single dose, single blind, placebo control, single center, single arm study in Type I diabetes patients. The study will include single dose administration for the evaluation of single dose acute toxicity, pharmacokinetics and activity.

Details

Lead sponsor	Oshadi Drug Administration
Phase	Phase 1
Status	COMPLETED
Enrolment	8
Start date	2010-10
Completion	2011-02

Conditions

• Diabetes

Interventions

• Oshadi Oral Insulin

Primary outcomes

• Adverse events occurrence — one month

Countries

Israel